Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
131 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Kidney Fibrosis - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Fibrosis - Pipeline Review, H2 2016, provides an overview of the Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline landscape. Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors and exposure to chemicals or radiation. Symptoms include pain, problems related to urination, nausea and vomiting. The condition may be managed with medication and kidney transplant. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Fibrosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Kidney Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 3, 21 and 7 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively for Kidney Fibrosis. Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Fibrosis (Genito Urinary System And Sex Hormones). - The pipeline guide reviews pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Kidney Fibrosis Overview 10 Therapeutics Development 11 Pipeline Products for Kidney Fibrosis - Overview 11 Pipeline Products for Kidney Fibrosis - Comparative Analysis 12 Kidney Fibrosis - Therapeutics under Development by Companies 13 Kidney Fibrosis - Therapeutics under Investigation by Universities/Institutes 15 Kidney Fibrosis - Pipeline Products Glance 16 Clinical Stage Products 16 Early Stage Products 17 Kidney Fibrosis - Products under Development by Companies 18 Kidney Fibrosis - Products under Investigation by Universities/Institutes 20 Kidney Fibrosis - Companies Involved in Therapeutics Development 21 AbbVie Inc 21 Angion Biomedica Corp. 22 Bio-inRen 23 BiOrion Technologies B.V. 24 Cellmid Limited 25 Epigen Biosciences, Inc. 26 Evotec AG 27 Galectin Therapeutics, Inc. 28 GenKyoTex S.A. 29 Intercept Pharmaceuticals, Inc. 30 Isarna Therapeutics GmbH 31 Lpath, Inc. 32 MorphoSys AG 33 Pharmaxis Limited 34 ProMetic Life Sciences Inc. 35 Raptor Pharmaceutical Corp. 36 Regulus Therapeutics Inc. 37 Symic Biomedical, Inc. 38 Tobira Therapeutics, Inc. 39 Vascular Biogenics Ltd. 40 Kidney Fibrosis - Therapeutics Assessment 41 Assessment by Monotherapy Products 41 Assessment by Target 42 Assessment by Mechanism of Action 45 Assessment by Route of Administration 48 Assessment by Molecule Type 50 Drug Profiles 52 ANG-3070 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 ANG-3586 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 ANG-4021 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 BOT-191 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 BRN-1889 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 CAB-102 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 cenicriviroc mesylate - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 CT-140 - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 cysteamine DR - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 Drug to Inhibit Galectin-3 for Liver Fibrosis, Respiratory Disorder and Kidney Fibrosis - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 Drugs for Tissue Fibrosis - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 GKT-136901 - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 GRMD-02 - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 ICG-001 - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 INT-767 - Drug Profile 91 Product Description 91 Mechanism Of Action 91 R&D Progress 91 ISTH-0047 - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 LJ-1888 - Drug Profile 94 Product Description 94 Mechanism Of Action 94 R&D Progress 94 Lpathomab - Drug Profile 95 Product Description 95 Mechanism Of Action 95 R&D Progress 95 melittin - Drug Profile 98 Product Description 98 Mechanism Of Action 98 R&D Progress 98 MOR-107 - Drug Profile 99 Product Description 99 Mechanism Of Action 99 R&D Progress 99 P-007 - Drug Profile 100 Product Description 100 Mechanism Of Action 100 R&D Progress 100 PBI-4050 - Drug Profile 101 Product Description 101 Mechanism Of Action 101 R&D Progress 101 PBI-4419 - Drug Profile 106 Product Description 106 Mechanism Of Action 106 R&D Progress 106 PXS-4820 - Drug Profile 107 Product Description 107 Mechanism Of Action 107 R&D Progress 107 PXS-5033A - Drug Profile 108 Product Description 108 Mechanism Of Action 108 R&D Progress 108 Recombinant Protein to Agonize ALK and BMP Receptors for Alport Syndrome, Kidney Diseases, Metabolic Disorders and Osteoarthritis - Drug Profile 109 Product Description 109 Mechanism Of Action 109 R&D Progress 109 RG-012 - Drug Profile 111 Product Description 111 Mechanism Of Action 111 R&D Progress 111 SB-300 - Drug Profile 114 Product Description 114 Mechanism Of Action 114 R&D Progress 114 Small Molecule to Antagonize AlphaVBetaI for Fibrosis - Drug Profile 115 Product Description 115 Mechanism Of Action 115 R&D Progress 115 Small Molecules to Antagonize LPA1 Receptor for Metastatic Breast Cancer and Renal Fibrosis - Drug Profile 116 Product Description 116 Mechanism Of Action 116 R&D Progress 116 Small Molecules to Inhibit Cyclophilin D for Obesity and Renal Fibrosis - Drug Profile 117 Product Description 117 Mechanism Of Action 117 R&D Progress 117 Small Molecules to Inhibit SphK2 for Autoimmune Disorders, Chronic Kidney Disease, Fibrosis, Neurodegenerative Diseases and Oncology - Drug Profile 118 Product Description 118 Mechanism Of Action 118 R&D Progress 118 SOL-1 - Drug Profile 119 Product Description 119 Mechanism Of Action 119 R&D Progress 119 Synthetic Peptides to Agonize BMP7 Receptor for Renal Fibrosis - Drug Profile 120 Product Description 120 Mechanism Of Action 120 R&D Progress 120 VB-703 - Drug Profile 121 Product Description 121 Mechanism Of Action 121 R&D Progress 121 Kidney Fibrosis - Dormant Projects 122 Kidney Fibrosis - Product Development Milestones 123 Featured News & Press Releases 123 Jul 12, 2016: Galectin Therapeutics Receives Notice of Australian Patent to be Granted for the Use of GR-MD-02 in Liver, Kidney, Lung or Heart Fibrosis 123 Nov 12, 2015: Regulus Announces Grant of Patent Covering Lead microRNA Therapeutics 123 Nov 09, 2015: ProMetic's PBI-4050 data on renal fibrosis and pancreatic function featured at the American Society of Nephrology's annual meeting 124 Oct 05, 2015: Regulus to Present Additional Preclinical Data Supporting RG-012 as a Novel microRNA Therapeutic in Development for Alport Syndrome at ASN's Kidney Week 2015 125 Aug 13, 2015: Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases 127 Oct 14, 2014: Regulus Therapeutics To Present New Preclinical Data on Multiple Programs At 10th Annual Oligonucleotide Therapeutics Society Meeting 127 Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter 128 Jul 25, 2014: Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis 128 Nov 01, 2012: Prometic Life Sciences Presents Positive Data On New Anti-fibrotic Drug PBI-4419 At American Society Of Nephrology Annual Meeting 129 Appendix 130 Methodology 130 Coverage 130 Secondary Research 130 Primary Research 130 Expert Panel Validation 130 Contact Us 130 Disclaimer 131
List of Tables
Number of Products under Development for Kidney Fibrosis, H2 2016 11 Number of Products under Development for Kidney Fibrosis - Comparative Analysis, H2 2016 12 Number of Products under Development by Companies, H2 2016 13 Number of Products under Development by Companies, H2 2016 (Contd..1) 14 Number of Products under Investigation by Universities/Institutes, H2 2016 15 Comparative Analysis by Clinical Stage Development, H2 2016 16 Comparative Analysis by Early Stage Development, H2 2016 17 Products under Development by Companies, H2 2016 18 Products under Development by Companies, H2 2016 (Contd..1) 19 Products under Investigation by Universities/Institutes, H2 2016 20 Kidney Fibrosis - Pipeline by AbbVie Inc, H2 2016 21 Kidney Fibrosis - Pipeline by Angion Biomedica Corp., H2 2016 22 Kidney Fibrosis - Pipeline by Bio-inRen, H2 2016 23 Kidney Fibrosis - Pipeline by BiOrion Technologies B.V., H2 2016 24 Kidney Fibrosis - Pipeline by Cellmid Limited, H2 2016 25 Kidney Fibrosis - Pipeline by Epigen Biosciences, Inc., H2 2016 26 Kidney Fibrosis - Pipeline by Evotec AG, H2 2016 27 Kidney Fibrosis - Pipeline by Galectin Therapeutics, Inc., H2 2016 28 Kidney Fibrosis - Pipeline by GenKyoTex S.A., H2 2016 29 Kidney Fibrosis - Pipeline by Intercept Pharmaceuticals, Inc., H2 2016 30 Kidney Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2016 31 Kidney Fibrosis - Pipeline by Lpath, Inc., H2 2016 32 Kidney Fibrosis - Pipeline by MorphoSys AG, H2 2016 33 Kidney Fibrosis - Pipeline by Pharmaxis Limited, H2 2016 34 Kidney Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2016 35 Kidney Fibrosis - Pipeline by Raptor Pharmaceutical Corp., H2 2016 36 Kidney Fibrosis - Pipeline by Regulus Therapeutics Inc., H2 2016 37 Kidney Fibrosis - Pipeline by Symic Biomedical, Inc., H2 2016 38 Kidney Fibrosis - Pipeline by Tobira Therapeutics, Inc., H2 2016 39 Kidney Fibrosis - Pipeline by Vascular Biogenics Ltd., H2 2016 40 Assessment by Monotherapy Products, H2 2016 41 Number of Products by Stage and Target, H2 2016 43 Number of Products by Stage and Mechanism of Action, H2 2016 46 Number of Products by Stage and Route of Administration, H2 2016 49 Number of Products by Stage and Molecule Type, H2 2016 51 Kidney Fibrosis - Dormant Projects, H2 2016 122
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
